Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

BACKGROUND: Adjuvant bisphosphonates are associated with improved breast cancer survival in postmenopausal patients. Addition of zoledronic acid (ZA) to neoadjuvant chemotherapy did not improve pathological complete response in the phase III NEOZOTAC trial. Here we report the results of the secondar...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res
Main Authors: de Groot, Stefanie, Pijl, Hanno, Charehbili, Ayoub, van de Ven, Saskia, Smit, Vincent T. H. B. M., Meershoek-Klein Kranenbarg, Elma, Heijns, Joan B., van Warmerdam, Laurence J. C., Kessels, Lonneke W., Dercksen, M. Wouter, Pepels, Manon J. A. E., van Laarhoven, Hanneke W. M., Vriens, Birgit E. P. J., Putter, Hein, Fiocco, Marta, Liefers, Gerrit-Jan, van der Hoeven, Jacobus J. M., Nortier, Johan W. R., Kroep, Judith R.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6712613/
https://ncbi.nlm.nih.gov/pubmed/31455425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-019-1180-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados